Safety
ADVERSE REACTIONS, ADVERSE EVENT
After enrollment, the median number of interventional therapy was two times (1-9 times), and the cumulative total number of interventional therapy was 203 times. The median treatment period for camrelizumab was 6 cycles (range 1-25). The adverse reactions during the observation period are shown in Adverse events.